An mRNA-based seasonal flu vaccine from Moderna was 27 percent more effective at preventing influenza infections than a standard flu shot, the company announced this week.
Moderna noted that the new shot, dubbed mRNA-1010, hit the highest efficacy target that it set for the trial, which included nearly 41,000 people aged 50 and above. Participants were randomly assigned to receive either mRNA-1010 or a standard shot and were then followed for about six months during a flu season.
Compared to the standard shot, the mRNA vaccine had an overall vaccine efficacy that was 26.6 percent higher, and 27.4 percent higher in participants who were aged 65 years or older. Previous trial data showed that mRNA-1010 generated higher immune responses in participants than both regular standard flu shots and high-dose flu shots.
The company noted that the positive results for the new trial come in the wake of one of the worst flu seasons in years. During the 2024–2025 flu season, the Centers for Disease Control and Prevention estimates that 770,000 people in the US were hospitalized for the flu.
“Today’s strong Phase 3 efficacy results are a significant milestone in our effort to reduce the burden of influenza in older adults,” Moderna CEO Stéphane Bancel said in a statement. “The severity of this past flu season underscores the need for more effective vaccines. An mRNA-based flu vaccine has the potential advantage to more precisely match circulating strains, support rapid response in a future influenza pandemic, and pave the way for COVID-19 combination vaccines.”
